Physician profile
Alan J Schecter
NPI 1407895774
$103,228.23
in general payments reported to CMS, 2019-2025
38 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $34K · 2021: $3,783 · 2022: $2,060 · 2023: $1,676 · 2024: $2,155 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,900.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $63,991.04 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $12,129.73 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $7,477.17 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $7,464.30 | 2019 | |
| Genentech USA, INC. | $3,400.10 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,228.20 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $1,004.19 | 2019-2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $671.03 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $623.21 | 2019-2025 | Dupixent |
| Genzyme Corporation | $526.57 | 2019-2025 | |
| Insmed, INC. | $448.70 | 2019-2025 | Arikayce, Brinsupri |
| Advanced Respiratory, INC | $305.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $301.88 | 2020-2022 | |
| Electromed, INC. | $287.57 | 2019-2025 | Smartvest |
| Philips North America LLC | $286.32 | 2019-2025 | Vest Therapy Und |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $251.12 | 2019-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $234.28 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $208.12 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $193.11 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $178.55 | 2020-2022 | |
| Pfizer INC. | $157.67 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.60 | 2021-2024 | |
| Olympus America INC. | $125.00 | 2022 | |
| Amgen INC. | $93.97 | 2022-2023 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $81.75 | 2019-2021 | |
| Inspire Medical Systems, INC. | $62.90 | 2025 | Inspire |
| Shire North American Group INC | $55.95 | 2019 | |
| Merck Sharp & Dohme LLC | $50.82 | 2023 | Pneumovax 23, Vaxneuvance |
| Shionogi INC | $41.60 | 2021-2024 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $38.55 | 2020 | |
| Circassia INC. | $38.09 | 2019 | |
| Mallinckrodt Enterprises LLC | $26.96 | 2019 | |
| United Therapeutics Corporation | $25.45 | 2025 | Tyvaso |
| Alexion Pharmaceuticals, INC. | $24.26 | 2023 | Ultomiris |
| Melinta Therapeutics, LLC | $21.06 | 2023 | Kimyrsa, Rezzayo, Vabomere |
| E.R. Squibb & Sons, L.L.C. | $18.64 | 2020 | |
| Gilead Sciences, INC. | $12.70 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Schecter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.